Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Part 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AB-101 | DRUG | AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents. |
| Placebo | DRUG | A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study. |
| Nucleos(t)ide Analogue | DRUG | Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B. |
Inclusion Criteria: Part 1 and 2 (Healthy Volunteers) * Male between ages 18-50 years * Willing and able to provide informed consent Willing to follow protocol-specified contraception requirement Inclusion Criteria: Part 3 (CHB Subjects) * Male or female subjects between the ages of 18-60 years ...
AB-101 is an investigational small molecule being developed for the treatment of chronic hepatitis B. It is currently in Phase 1 clinical development and has been studied in healthy volunteers and subjects with chronic hepatitis B.
AB-101 is being developed by Arbutus Biopharma Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ABUS.
AB-101 is in Phase 1 clinical development. A Phase 1 trial evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics has been completed.
AB-101 has been studied in a Phase 1 clinical trial registered as NCT05960240. This trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB-101 following oral administration in healthy subjects and subjects with chronic hepatitis B.
AB-101 is the investigational name used by Arbutus Biopharma for this small molecule candidate. No alternative names have been reported for this drug.